Maltese researchers have developed a new blood test capable of detecting and analysing cancer-related particles using extremely small sample volumes, marking a significant step forward in early diagnosis and treatment monitoring.According to a report by the Times of Malta, the innovation forms part of the M3Profiler project, led by Omnigene Medical Technology Ltd. and financed by Xjenza Malta.The test focuses on tumour-derived vesicles, microscopic particles released by cancer cells into the bloodstream, which are increasingly used as biomarkers for diagnosing and monitoring disease.Researchers have developed a droplet-based system that enhances detection sensitivity while significantly reducing the amount of blood plasma required.By breaking samples into microscopic droplets, scientists can identify and analyse these particles even when present in very low concentrations.The system is capable of analysing more than 12 different antigens from a single low-volume sample, allowing for detailed tumour profiling without the need for invasive biopsies.The technology could improve early tumour detection, enable real-time monitoring of treatment effectiveness, and help identify disease recurrence at an earlier stage.Validation of the system is currently being carried out by the University of Malta, with researchers aiming to assess its performance across different cancer types.If successfully introduced into clinical practice, the Maltese-developed test could play a key role in advancing personalised cancer treatment and improving patient outcomes.Is more investment needed in research?•